| Median (range) | Count (%) |
---|---|---|
Continuous variables | Â | Â |
  Age (years) | 70 (54–86) |  |
  Initial PSA (ng/mL) | 11.95 (3.7–48.0) |  |
  Positive biopsy rate (%) | 33.0 (13.0–100) |  |
  Prostate D90 (Gy) | 124.8 (100.0–206.5) |  |
  BED (Gy2) | 213.5 (178.5–245.5) |  |
Categorical variables | Â | Â |
  PSA level in ng/mL |  |  |
   <10 |  | 86 (41.7%) |
   10-20 |  | 39 (19.0%) |
   ≥ 20 |  | 81 (39.3%) |
  Gleason score |  |  |
   5-6 |  | 26 (12.6%) |
   7 |  | 54 (26.2%) |
   8-10 |  | 126 (61.2%) |
  Clinical T stage |  |  |
   T1-T2a |  | 142 (69.0%) |
   T2b-T2c |  | 46 (22.4%) |
   T3a |  | 18 (8.6%) |
  No. of high-risk features |  |  |
   1 |  | 186 (90.3%) |
   2 |  | 19 (9.2%) |
   3 |  | 1 (0.5%) |
  Neoadjuvant ADT |  |  |
   Yes |  | 101 (49.0%) |